Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Clinical Pharmacology and Therapeutics|August 5, 2024
Coproporphyrin-I as a Selective OATP1B Biomarker Can Be Used to Delineate the Mechanisms of Complex Drug-Drug Interactions: Cedirogant Case StudyRyota Kikuchi, Yuli Qian, Mohamed Badawi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 27, 2026
Changing Cirrhosis Burden in the MENA Region, 1990-2021: From Premature Mortality to Disability (Global Burden of Disease)Razan Emad, Siham AlSinani, Mohamed El-Kassas, et al.
Clinical Therapeutics|August 14, 2024
Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic DermatitisYuli Qian, Eliza M Raymundo, Shuai Hao, et al.
Pharmacogenetics and Genomics|January 14, 2011
Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patientsMohamed Hossam A Shahin, Sherief I Khalifa, Yan Gong, et al.
Arthritis Care & Research|November 14, 2024
Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open-Label, Phase 1 TrialHermine I Brunner, Anna Shmagel, Gerd Horneff, et al.
Clinical and Experimental Dermatology|May 3, 2024
Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trialStephen Tyring, Angela Moore, Akimchi Morita, et al.
Clinical Pharmacology and Therapeutics|July 7, 2026
Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk MitigationTommy Li, Andrew Tredennick, Daniel Polhamus, et al.
Clinical and Translational Science|December 19, 2023
Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasisMohamed-Eslam F Mohamed, Yuli Qian, Ronilda D'Cunha, et al.
The Journal of Allergy and Clinical Immunology|December 2, 2019
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trialEmma Guttman-Yassky, Diamant Thaçi, Aileen L Pangan, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 26, 2024
Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled TrialJoan T Merrill, Yoshiya Tanaka, David D'Cruz, et al.
Pageof 8